SEPETAPROST

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H36F2O6
Molecular Weight	482.5572
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)COC3=C(F)C=CC(F)=C3)[C@@]1([H])CC[C@H](CCCC(=O)OC(C)C)CO2

InChI

InChIKey=BKVUSNOUTQMSBE-XCMGCKIWSA-N

InChI=1S/C26H36F2O6/c1-16(2)34-26(31)5-3-4-17-6-9-21-20(23(30)13-24(21)32-14-17)10-8-19(29)15-33-25-12-18(27)7-11-22(25)28/h7-8,10-12,16-17,19-21,23-24,29-30H,3-6,9,13-15H2,1-2H3/b10-8+/t17-,19+,20+,21+,23+,24-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C26H36F2O6
Molecular Weight	482.5572
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	1
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26720443 | https://clinicaltrials.gov/ct2/show/NCT02083289

Sepetoprost (also known as ONO-9054), prostaglandin analog was developed as a dual agonist of prostaglandin E3 (EP3) and prostaglandin F (FP) receptors. It is known, that the use of a dual prostaglandin EP3 and prostaglandin F receptor agonists is a novel approach for the reduction of intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. Sepetoprost was successfully studied in clinical trials phase II for the treatment of open-angle glaucoma, ocular hypertension, and mild open angle-glaucoma.

Originator

Approval Year

PubMed

Title	Date	PubMed
A Novel Dual Agonist of EP3 and FP Receptors for OAG and OHT: Safety, Pharmacokinetics, and Pharmacodynamics of ONO-9054 in Healthy Volunteers.	2015 Dec	26720443
Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study.	2016 Oct	27300645
Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma.	2019 Apr	29669171

Patents

Sample Use Guides

In Vivo Use Guide

Nine subjects were randomized to each of ONO-9054 (sepetaprost) 3, 10, 20, 30 μg/mL and 12 to placebo. Subjects received a single drop to each eye at 07:00±30 minutes (single dose). Following a 4-day no-treatment period, subjects were dosed once daily for 14 consecutive days (multiple day dosing)

Route of Administration: Other

Substance Class	Chemical Created by `admin` on `Sat Dec 16 09:47:05 GMT 2023` Edited by `admin` on `Sat Dec 16 09:47:05 GMT 2023`
Record UNII	79O7855J4G
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SEPETAPROST

Official Name

English

DE-126

Code

English

2H-CYCLOPENT(B)OXEPIN-3-BUTANOIC ACID, 6-((1E,3R)-4-(2,5-DIFLUOROPHENOXY)-3-HYDROXY-1-BUTEN-1-YL)OCTAHYDRO-7-HYDROXY-, 1-METHYLETHYL ESTER, (3S,5AR,6R,7R,8AS)-

Systematic Name

English

ONO-9054

Code

English

2-PROPANYL 4-((3S,5AR,6R,7R,8AS)-6-((1E,3R)-4-(2,5-DIFLUOROPHENOXY)-3-HYDROXY-1-BUTEN-1-7-HYDROXYOCTAHYDRO-2H-CYCLOPENTA(B)OXEPIN-3-YL)BUTANOATE

Systematic Name

English

STN-1012600

Code

English

Sepetaprost [WHO-DD]

Common Name

English

STN1012600

Code

English

sepetaprost [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29705